Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

BACKGROUND: Pharmacokinetic advantages of intraperitoneal (IP) rhIL-12, tumor response to IP delivery of other cytokines as well as its potential anti-angiogenic effect provided the rationale for further evaluation of IPrhIL-12 in patients with persistent ovarian or peritoneal carcinoma. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenzi, Renato, Edwards, Robert, June, Carl, Seiden, Michael V, Garcia, Michael E, Rosenblum, Michael, Freedman, Ralph S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248163/
https://www.ncbi.nlm.nih.gov/pubmed/18076766
http://dx.doi.org/10.1186/1479-5876-5-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248163/
https://www.ncbi.nlm.nih.gov/pubmed/18076766
http://dx.doi.org/10.1186/1479-5876-5-66

Ejemplares similares